Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zoetis (ZTS)
NYSE:ZTS
Holding ZTS?
Track your performance easily
ZTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$144.80 - $200.53
Previous CloseN/A
Volume625.10K
Average Volume (3M)2.55M
Market Cap
$74.84B
Enterprise Value$93.65B
Total Cash (Recent Filing)$727.00M
Total Debt (Recent Filing)$4.47B
Price to Earnings (P/E)31.2
Beta0.85
Next Earnings
Feb 13, 2025EPS Estimate
1.38Last Dividend Ex-Date
Jan 21, 2025Dividend Yield1.04%
Share Statistics
EPS (TTM)5.32
Shares Outstanding451,165,000
10 Day Avg. Volume2,931,455
30 Day Avg. Volume2,552,311
Standard Deviation0.07
R-Squared0.42
Alpha-0.00348
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.18
Price to Cash Flow (P/CF)19.70
P/FCF Ratio22.60
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue10.23
Enterprise Value/Gross Profit15.65
Enterprise Value/Ebitda24.48
Forecast
1Y Price Target
$214.44Price Target Upside29.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Zoetis News
PremiumCompany Announcements
Zoetis Highlights Growth at J.P. Morgan Conference
PremiumCompany Announcements
Zoetis Boosts Dividend by 16% for 2025
PremiumCompany Announcements
Zoetis Announces Major Leadership Changes for GrowthBulls Say, Bears Say
Bulls Say
Growth ProspectsStrong demand for companion animal dermatology products is expected to positively impact revenue.
Market ExpansionZoetis has benefited from being a first mover in several markets, including triple-action parasiticides, dermatology, and osteoarthritis pain.
Product Safety And AdoptionVeterinarians appear more comfortable with the safety profile of Zoetis's oral JAK inhibitor Apoquel over a competitor's oral JAK which has a black box warning in the US.
Bears Say
Market CompetitionThere is a likely period where Elanco's IL-31 mAb will be on the market before Zoetis's longer-acting IL-31 mAb is approved, which could affect Zoetis's competitive position.
Product LaunchA slower quarterly ramp in Librela sales in the US is expected, affecting the launch trajectory negatively from a quarter-over-quarter growth perspective.
Safety ConcernsLibrela has been the subject of heightened controversy this year, as safety concerns surfaced and became an overhang on ZTS shares.
---
Ownership Overview
0.06% Insiders
19.93% Mutual Funds
0.97% Other Institutional Investors
57.97% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZTS FAQ
What was Zoetis’s price range in the past 12 months?
Zoetis lowest stock price was $144.80 and its highest was $200.53 in the past 12 months.
What is Zoetis’s market cap?
Zoetis’s market cap is $74.84B.
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is Feb 13, 2025 which is in 21 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on Nov 04, 2024. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.456 by $0.124.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Undervalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $1.796 which represents an annual dividend yield of 1.04%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is 1.38.
How many shares outstanding does Zoetis have?
Zoetis has 451,165,000 shares outstanding.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.58 in its last earnings report, beating expectations of $1.456. Following the earnings report the stock price went down -3.721%.
Which hedge fund is a major shareholder of Zoetis?
Among the largest hedge funds holding Zoetis’s share is Intermede Investment Partners Ltd. It holds Zoetis’s shares valued at 144M.
---
Zoetis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$214.44 (29.27% Upside)
$214.44 (29.27% Upside)
Blogger Sentiment
Bullish
ZTS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 348.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $617.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.24%
12-Months-Change
Fundamentals
Return on Equity
46.43%
Trailing 12-Months
Asset Growth
1.78%
Trailing 12-Months
Company Description
Zoetis
Founded in 1952, New Jersey-based Zoetis, Inc. is the world's largest manufacturer of medicine and vaccinations for pets and livestock in the United States and internationally. Its products are complemented by diagnostic products, genetic tests, bio devices and services.
---
ZTS Company Deck
---
ZTS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance for Zoetis, with significant growth in revenue and key product portfolios, particularly in companion animal products. Despite some challenges in the China market and the impact of strategic divestitures, the company remains confident in its growth trajectory and market leadership.Read More>---
ZTS Revenue Breakdown
65.26% Companion animal
33.82% Livestock
0.91% Contract manufacturing & human health
---
ZTS Stock 12 Month Forecast
Average Price Target
$214.44
▲(29.27% Upside)
Technical Analysis
Idexx Laboratories
―
Elanco Animal Health
―
AngioDynamics
―
Neogen
―
Bristol-Myers Squibb
―
AbbVie
―
Best Analysts Covering ZTS
1 Year
1 Year Success Rate
16/21 ratings generated profit
1 Year Average Return
+18.71%
reiterated a buy rating 3 months ago
Copying Erin Wright's trades and holding each position for 1 Year would result in 76.19% of your transactions generating a profit, with an average return of +18.71% per trade.
---